Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revelation BiosciencesREVB 28 Cash-to-Debt is 15.52 as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,397 Biotechnology companies, Revelation Biosciences ranks better than 59.48% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Revelation Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 15.52.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Revelation Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Revelation Biosciences's Cash-to-Debt or its related term are showing as below:
REVB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 14.32 Med: No Debt Max: No Debt
Current: 15.52
During the past 6 years, Revelation Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 14.32. And the median was No Debt.
REVB's Cash-to-Debt is ranked better than 59.48% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs REVB: 15.52
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Revelation Biosciences Cash-to-Debt Related Terms
Revelation Biosciences Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Revelation Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revelation Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences (REVB) has a Cash-to-Debt of 15.52 as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Revelation Biosciences' Cash-to-Debt has ranged from 14.32 to 10,000.00. According to the industry distribution chart, Revelation Biosciences ranks #566 out of 1397 companies in the Biotechnology industry, placing it in the top 40.5%.
Is Revelation Biosciences' Cash-to-Debt too high?
Revelation Biosciences' current Cash-to-Debt of 15.52 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 14.32 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Revelation Biosciences' value of 15.52 is 131% above this industry median. Based on the distribution chart, Revelation Biosciences ranks #566 out of 1397 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Cash-to-Debt compare to TCRT and MBIO?
According to the Biotechnology industry distribution chart, Revelation Biosciences ranks #566 out of 1397 companies for Cash-to-Debt. This puts Revelation Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 6.72. Revelation Biosciences' value of 15.52 is 131% above this benchmark. Historically, Revelation Biosciences' own Cash-to-Debt has ranged from 14.32 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 6.72, Revelation Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revelation Biosciences's current Cash-to-Debt of 15.52 is 131% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revelation Biosciences's current Cash-to-Debt is 15.52, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Cash-to-Debt of 15.52. The current Cash-to-Debt is 15.52, which is 100% below median its 10-year median of 10,000.00 and 131% above the Biotechnology industry median of 6.72. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Cash-to-Debt is 15.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score
Get the complete analysis for REVB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVB has been successfully added to your 
